Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma


28 Sep 2019


Poster Display session 1


Tumour Site

Multiple Myeloma


Ching-Liang Ho


Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251


C. Ho1, J. Chen2

Author affiliations

  • 1 Medical Department, Tri-Service General Hospital, National Defense Medical Center, 114 - Taipei/TW
  • 2 Medical Department, Tri-Service General Hospital, National Defense Medical Center, 11490 - Taipei/TW


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 836


In this retrospective cohort study based in Taiwan, we reported the current epidemiology of patients with multiple myeloma and analyzed the effect of bortezomib-based therapy on clinical outcomes.


We identified 5726 patients with newly diagnosed multiple myeloma (MM) between 2007 and 2015 in Taiwan. Privileges data from the National Health Institute Research Database was used, as it is made readily available to the public in electronic format for research purposes.


Among them, from January 2007 to October 2011, there were 1116 multiple myeloma patients (control group: bortezomib as non-first-line drug), and there were 4610 multiple myeloma patients from November 2011 to December 2015.The results showed that in the case group the proportion of hospital deaths in the future was 15.73% (702/4464), while the proportion of hospital deaths in the control group was 19.80% (221/1116). The patient with first-line with bone marrow transplantation, the first-line without bone marrow transplantation, the non-first-line with bone marrow transplantation, the probability of hospital death risk was 0.387 times higher than that of the non-first-line without bone marrow transplantation) (P < 0.001) ), 0.681 times (P < 0.001), 0.724 times (P = 0.035).


In conclusion, our study showed that the first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma was better than the non-first line. To provide the most representative data on Bortezomib treatment results of MM patients achievable in Taiwan, we could prospectively collect nationwide data including detailed information. This could not only provide stage-stratified survival and disease-specific survival rates but also help to identify better clinical effects.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.